Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia

Leuk Lymphoma. 2018 Sep;59(9):2258-2260. doi: 10.1080/10428194.2017.1410890. Epub 2017 Dec 18.

Authors

Nathan D Gay¹, Eliana Kozin², Craig Okada¹, Alexey V Danilov¹, Stephen Spurgeon¹

Affiliations

¹ a Oregon Health and Science University , Portland , OR , USA.
² b Tuality Healthcare , Portland , OR , USA.

PMID: 29249186
DOI: 10.1080/10428194.2017.1410890

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Disease-Free Survival
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Middle Aged
Neutropenia / chemically induced
Pneumonia / chemically induced
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
obinutuzumab